Although considered as a first-line drug for various types of cancers, one of the main obstacles to doxorubicin therapy is drug resistance [28], which is mainly mediated by ABCB1, for which doxorubicin represents a good substrate [29,30]. This evidence concerns the gene ABCB1 and cancer.